Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

BACKGROUND & AIMS: Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Gastroenterol Hepatol
Main Authors: Lynch, Kate D., Chapman, Roger W., Keshav, Satish, Montano-Loza, Aldo J., Mason, Andrew L., Kremer, Andreas E., Vetter, Marcel, de Krijger, Manon, Ponsioen, Cyriel Y., Trivedi, Palak, Hirschfield, Gideon, Schramm, Christoph, Liu, Chung Heng, Bowlus, Christopher L., Estes, Derek J., Pratt, Daniel, Hedin, Charlotte, Bergquist, Annika, de Vries, Annemarie C., van der Woude, C. Janneke, Yu, Lei, Assis, David N., Boyer, James, Ytting, Henriette, Hallibasic, Emina, Trauner, Michael, Marschall, Hanns-Ulrich, Daretti, Luigi M., Marzioni, Marco, Yimam, Kidist K., Perin, Nicola, Floreani, Annarosa, Beretta-Piccoli, Benedetta Terziroli, Rogers, Jennifer K., Levy, Cynthia
Formato: Artigo
Idioma:Inglês
Publicado: W.B. Saunders for the American Gastroenterological Association 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941216/
https://ncbi.nlm.nih.gov/pubmed/31100458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2019.05.013
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares